Elicio Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $33,656 | $23,849 |
| General and administrative | 11,330 | 11,896 |
| Total operating expenses | 44,986 | 35,745 |
| Loss from operations | (44,986) | (35,745) |
| Other (expense) income | ||
| Change in fair value of warrant liabilities | (3,886) | (2) |
| Loss on issuance of pre-funded warrants | (3,502) | — |
| Change in fair value of derivative liability | — | 429 |
| Gain on extinguishment of promissory notes payable | — | 605 |
| Gain on sale of equipment | 3 | — |
| Foreign exchange transaction gain | 151 | 204 |
| Interest income | 777 | 373 |
| Interest expense | (455) | (1,059) |
| Total other (expense) income, net | (6,912) | 550 |
| Provision for income taxes | — | — |
| Net loss | (51,898) | (35,195) |
| Other comprehensive gain (loss): | ||
| Foreign currency translation adjustment | 22 | (197) |
| Comprehensive loss | $(51,876) | $(35,392) |
| Net loss per common share, basic and diluted | $(4.25) | $(6.96) |
| Weighted average common shares outstanding, basic and diluted | 12,202,996 | 5,056,225 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.